CN1150035A - Glycolipid-gram pharmaceutical composition for treating diabetes mellitus - Google Patents

Glycolipid-gram pharmaceutical composition for treating diabetes mellitus Download PDF

Info

Publication number
CN1150035A
CN1150035A CN 95118914 CN95118914A CN1150035A CN 1150035 A CN1150035 A CN 1150035A CN 95118914 CN95118914 CN 95118914 CN 95118914 A CN95118914 A CN 95118914A CN 1150035 A CN1150035 A CN 1150035A
Authority
CN
China
Prior art keywords
parts
radix
diabetes
glycolipid
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 95118914
Other languages
Chinese (zh)
Other versions
CN1054524C (en
Inventor
陈金燕
林祖宪
扶春福
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN95118914A priority Critical patent/CN1054524C/en
Publication of CN1150035A publication Critical patent/CN1150035A/en
Application granted granted Critical
Publication of CN1054524C publication Critical patent/CN1054524C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention discloses a pharmaceutical composition for treating diabetes mellitus, which comprises the following raw materials in parts by weight: 10-20 parts of cortex lycii radicis, 10-20 parts of ginseng, 10-20 parts of trichosanthes root, 10-20 parts of radix rehmanniae, 5-10 parts of astragalus membranaceus, 5-10 parts of Chinese yam, 5-10 parts of schisandra chinensis, 5-10 parts of radix ophiopogonis, 5-10 parts of rhizoma polygonati, 5-10 parts of adenophora stricta, 5-10 parts of spina date seed, 5-10 parts of radix puerariae, 5-10 parts of arillus longan and 5-10 parts of corn stigma. The invention provides a new medicine-glycolipid gram I with good effect of reducing blood sugar and blood fat and small toxic and side effect for the patients with 'upper-grade' diabetes clinically.

Description

The glycolipid gram pharmaceutical composition of a kind of treatment " on disappear " type diabetes
The present invention relates to a kind of medicine for the treatment of diabetes, specifically is the Chinese patent medicine of feedstock production with the Chinese herbal medicine.
Diabetes are a kind of common endocrine-metabolic diseases.Its sickness rate has the trend that increases year by year, be listed in the third-largest disease after cardiovascular disease and tumor in developed country, deadly and the disability rate of diabetes and complication thereof has become world medicine man stubborn problem, annual countries in the world are expended huge fund this disease are studied, but produce little effect.At present the domestic and international chemical synthetic drug that adopts treats that to exist curative effect low, the defective that toxic and side effects is big, and for a long time with easily producing serious adverse reactions such as lactate acidemia, ketonemia, country such as U.S. has banned use of biguanides at present as: phenformin; Often curative effect is better in just with several weeks for sulfonylureas (tolbutamide, glyburide), and using after 6-12 month has patient 10-15% to lose curative effect suddenly, and reason is not bright, and the outstanding easily generation of old person serious ketoacidosis can take place and causes death.With producing antibody, biological activity reduces insulin for a long time, and dosage increases, and then causes regulatory mechanism compensation response-can cause hyperinsulinemia and blood glucose fluctuation.
The traditional Chinese medical herbal treatment diabetes have history remote, and the traditional Chinese medical science claims that diabetes are " diabetes ", and are divided into " on disappear ", " in disappear ", " diabetes due to kidney-deficiency " three types according to the primary and secondary difference of symptom performance.Based on polydipsia, polyuria, polyphagia take second place " on disappear "; Based on polyphagia, polydipsia, polyuria take second place " in disappear "; Based on polyuria, polydipsia, polyphagia take second place " diabetes due to kidney-deficiency ".Traditional treatment by Chinese herbs, the doctor needs according to different patients and dialectical evolution is very inconvenient, and patient is also very time-consuming bothersome when taking, and prescription drugs can not satisfy need of industrial production, so also be difficult to satisfy a large amount of patients' demand.At present domestic clinical also have adopt patent medicine to treat, but these Chinese patent medicines generally all are applied to diabetes (diabetes) generally, so poor effect.As the Radix Ginseng metformin that uses clinically (include the Radix Astragali, Radix Ginseng, pollen, the Radix Rehmanniae, Radix Ophiopogonis, know not, Gypsum Fibrosum, Poria, Rhizoma Dioscoreae, Radix Glycyrrhizae, Cortex Lycii, Stigma Maydis), it generally is used for treating diabetes, its effective percentage only is 63.3%, (see that the Kuang An Kun always edits, Hunan science tech publishing house publishes " diabetes are in China " P279), and according to the tcm syndrome differentiation and typing treatment, curative effect is then also low.Clinical present employed diabetes pill (include Radix Astragali 5%, the Radix Rehmanniae 15%, pollen 24%, every ball and contain glyburide 0.25mg) is though curative effect is better, because it includes chemical synthetic drug, so still there is the inherent defective of chemical synthetic drug.
The objective of the invention is to execute the improvement opinion, provide a kind of and be adapted to especially " on disappear " diabetes mellitus type according to differential diagnosis in tcm, and curative effect height, pharmaceutical composition that toxic and side effects is little.
The object of the present invention is achieved like this, based on pathogenetic understanding and the Therapeutic Principle of motherland's medical science to diabetes, dialectical executing controlled, the Shangxiao type diabetes patient is adopted lung moistening, lung heat clearing, promotes the production of body fluid, filter out in motherland's medical treasure-house that having quenches the thirst and moisturize, the Chinese herbal medicine of clearing away heat and nourishing YIN, and carry out reasonable compatibility, preparation saccharogenesis gram I number, make it in diabetes-alleviating polydipsia symptom, glucose level control effectively, and delay, stop the generation of diabetic complication.
Medicine of the present invention (glycolipid gram I number) is made (consumption is a weight portion) by following component:
Cortex Lycii 10-20 part, Radix Ginseng 10-20 part, Radix Trichosanthis 10-20 part, Radix Rehmanniae 0-20 part, Radix Astragali 5-10 part, Rhizoma Dioscoreae 5-10 part, Fructus Schisandrae Chinensis 5-10 part, Radix Ophiopogonis 5-10 part, Rhizoma Polygonati 5-10 part, Radix Adenophorae (Radix Glehniae) 5-10 part, Semen Ziziphi Spinosae 5-10 part, Radix Puerariae 5-10 part, Arillus Longan 5-10 part, Stigma Maydis 5-10 part.
The optimum weight proportioning of medicine of the present invention is:
Cortex Lycii 12-15 part, Radix Ginseng 12-15 part, Radix Trichosanthis 12-15 part, Radix Rehmanniae 12-15 part, Radix Astragali 5-7 part, Rhizoma Dioscoreae 5-7 part, Fructus Schisandrae Chinensis 5-7 part, Radix Ophiopogonis 5-7 part, Rhizoma Polygonati 5-7 part, Radix Adenophorae (Radix Glehniae) 5-7 part, Semen Ziziphi Spinosae 5-7 part, Radix Puerariae 5-7 part, Arillus Longan 5-7 part, Stigma Maydis 5-7 part.
Radix Ginseng in the present invention's prescription can substitute with the Leptoradix Ginseng.
Medicine of the present invention can be prepared into various oral formulations such as tablet, capsule, oral liquid, electuary.
Medication preparation of the present invention becomes the method for electuary (being glycolipid gram I electuary) to be:
1, the Radix Ginseng of said ratio weight is soaked separately decocted 1-2 hour, leave and take filtrate, medicinal residues decoct with water 1 hour, continue to employ (for ginseng liquid) filtrate merging twice, the medicinal residues oven dry, pulverize, and it is stand-by to cross 120 mesh sieves.
2, above-mentioned prescription (except that Radix Ginseng) is taken by weighing by proportioning weight, soaked 2 hours, decocted 1-2 hour, filter, leave and take filtrate, medicinal residues add water, decoct 1 hour, merge twice filtrate (for admixing medical solutions), and are stand-by, abandon medicinal residues.
3, Radix Ginseng medicinal liquid and admixing medical solutions are merged, be concentrated into thick paste after, add the Radix Ginseng powder, 120 mesh sieves are crossed in mixing, drying, pulverizing, sterilization, packing.
Medicine of the present invention is applicable to based on the polydipsia symptom, has the non-insulin-dependent diabetes mellitus of polyphagia, polyuria, fatigue and weak, dysphoria with feverish sensation in the chest palms and soles, constipation, the few tongue of red tongue, weak pulse or number or symptom such as unable concurrently.
The usage and dosage of medicine of the present invention is: each 5 grams, every day 4 times, half an hour ante cibum, clothes were last, had been taken at bed time.General logotype is after three months, look the state of an illness and the dose that cuts down according to the circumstance to maintenance dose (be every day 2-3 time).Still note diet, exercise and emotion during keeping treatment.
The important inventive point of medicine of the present invention is: the compatibility between the each component produces good nourishing YIN to lower pathogenic fire, the effect of slaking thirst and help produce saliva, the needs that adapted to " on disappear " diabetes mellitus type homeostasis, its " polydipsia " symptom obviously alleviates, and blood glucose, blood fat also obviously reduce.
The therapeutic effect of medicine of the present invention has obtained checking by system's clinical experiment of 100 routine patients.
Its experimental technique is:
1, the type ii diabetes people (meeting WHOII type diabetes diagnosis standard) of subjects, selection prescription on individual diagnosis, patient is based on the polydipsia symptom, have polyphagia, polyuria concurrently, other symptom has fatigue and weak, dysphoria with feverish sensation in the chest palms and soles, constipation, red tongue few tongue, weak pulse or number or unable.
2, randomized controlled design: with " on disappear " type diabetes patient of above-mentioned selection by sex, age, occupation, diabetic duration, diabetes family history, to have or not equilibriums such as concurrent hypertension or coronary heart disease, blood glucose, blood fat be two groups, be defined as test group (48 example) and matched group (52 example) with simple random sampling then, test group is taken each 5 grams of medicine of the present invention, four times a day, matched group is taken the Radix Ginseng metformin, each 5, every day 4 times, experimental result sees Table 1, table 2.
Table 1: blood glucose (mg/dl) situation of change in two groups of therapeutic processes
After treating February before the treatment
N X ± S n X ± S test group 48 210 ± 59 45 172 ± 42 * * matched groups, 52 190 ± 40 50 189 ± 45** represents P<0.01 table 2: the situation of change of triglyceride (mg/dl) in two groups of research process
After treating February before the treatment
N X ± S n X ± S test group 48 184 ± 82 45 161 ± 65 * matched group 52 188 ± 158 50 186 ± 178
* represent P<0.05
Above experimental result shows, medicine of the present invention all is better than the Radix Ginseng metformin to blood sugar lowering, the lipid-lowering effect of " on disappear " diabetes mellitus type, embody medicine of the present invention and complied with and debate the Therapeutic Principle that disease executing controlled, produced the not available good efficacy of Chinese patent medicine of existing treatment diabetes.It is 86% that medicine of the present invention is used for the treatment of " on disappear " its effective percentage of diabetes mellitus type, (criterion of therapeutical effect is with reference to " clinical disease diagnosis is according to curing the improvement standard " of The General Logistics Department of PLA's revision in 1987), the effect of agents alleviate diabetics polydipsia symptom of the present invention is significantly better than the remission effect of Radix Ginseng metformin.Medicine of the present invention is not found any toxic and side effects through clinic trial 2 years.So medicine of the present invention has the little new drug of definite curative effect toxic and side effects, and has made things convenient for clinicist's medication " on disappear " the type patient in the diabetes for the clinicist provides a kind of.
Embodiment 1:
1, take by weighing Radix Ginseng 20 grams, soaked 1 hour, decocted 1.5 hours, leave and take filtrate, medicinal residues boiled 1 hour after adding water again, and twice filtrate merges (being ginseng liquid), and medicinal residues are dried, pulverize, crossed 120 mesh sieves (being the Radix Ginseng powder), and are stand-by.
2, get Cortex Lycii 20 gram, Radix Trichosanthis 20 grams, the Radix Rehmanniae 20 grams, the Radix Astragali 10 grams, Rhizoma Dioscoreae 10 grams, Fructus Schisandrae Chinensis 10 grams, Radix Ophiopogonis 10 gram, Rhizoma Polygonati 10 grams, Radix Adenophorae (Radix Glehniae) 10 grams, Semen Ziziphi Spinosae 10 grams, Radix Puerariae 10 grams, Arillus Longan 10 grams, Stigma Maydis 10 grams, add water to submerge, steeped 2 hours, decocted 1.5 hours, filter, leave and take filtrate, medicinal residues add water, decoct 1 hour again, merge twice medicinal liquid (for admixing medical solutions), continue to employ, discard medicinal residues.
3, Radix Ginseng medicinal liquid and admixing medical solutions are merged, be concentrated into thick paste after, add Radix Ginseng powder, drying, pulverizing, cross 120 mesh sieves, sterilization, packing.
The preparation method of embodiment 2-5 is with embodiment 1, and just the weight proportion of prescription is different, and curative effect is suitable substantially, and is wherein remarkable with embodiment 3 curative effects.
Figure A9511891400091

Claims (2)

  1. The glycolipid gram pharmaceutical composition of 1, a kind of treatment " on disappear " diabetes is characterized in that it is made up of following materials of weight proportions:
    Cortex Lycii 10-20 part, Radix Ginseng 10-20 part, Radix Trichosanthis 10-20 part, Radix Rehmanniae 10-20 part, Radix Astragali 5-10 part, Rhizoma Dioscoreae 5-10 part, Fructus Schisandrae Chinensis 5-10 part, Radix Ophiopogonis 5-10 part, Rhizoma Polygonati 5-10 part, Radix Adenophorae (Radix Glehniae) 5-10 part, Semen Ziziphi Spinosae 5-10 part, Radix Puerariae 5-10 part, Arillus Longan 5-10 part, Stigma Maydis 5-10 part.
  2. The glycolipid gram pharmaceutical composition of 2, treatment according to claim 1 " on disappear " type diabetes is characterized in that it is made up of the medicine of following weight proportioning:
    Cortex Lycii 12-15 part, Radix Ginseng 12-15 part, Radix Trichosanthis 12-15 part, Radix Rehmanniae 12-15 part, Radix Astragali 5-7 part, Rhizoma Dioscoreae 5-7 part, Fructus Schisandrae Chinensis 5-7 part, Radix Ophiopogonis 5-7 part, Rhizoma Polygonati 5-7 part, Radix Adenophorae (Radix Glehniae) 5-7 part, Semen Ziziphi Spinosae 5-7 part, Radix Puerariae 5-7 part, Arillus Longan 5-7 part, Stigma Maydis 5-7 part.
CN95118914A 1995-11-10 1995-11-10 Medicine composition for treating diabetes mellitus Expired - Fee Related CN1054524C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN95118914A CN1054524C (en) 1995-11-10 1995-11-10 Medicine composition for treating diabetes mellitus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN95118914A CN1054524C (en) 1995-11-10 1995-11-10 Medicine composition for treating diabetes mellitus

Publications (2)

Publication Number Publication Date
CN1150035A true CN1150035A (en) 1997-05-21
CN1054524C CN1054524C (en) 2000-07-19

Family

ID=5081813

Family Applications (1)

Application Number Title Priority Date Filing Date
CN95118914A Expired - Fee Related CN1054524C (en) 1995-11-10 1995-11-10 Medicine composition for treating diabetes mellitus

Country Status (1)

Country Link
CN (1) CN1054524C (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100339119C (en) * 2005-11-03 2007-09-26 蔡青 Traditional Chinese medicine prepns. for treating diabete
CN101062256B (en) * 2007-05-26 2010-12-01 李丰军 Chinese traditional combination medicine for treating diabetes
CN102895537A (en) * 2011-07-27 2013-01-30 陈冠卿 Medicine treating diabetes

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100339119C (en) * 2005-11-03 2007-09-26 蔡青 Traditional Chinese medicine prepns. for treating diabete
CN101062256B (en) * 2007-05-26 2010-12-01 李丰军 Chinese traditional combination medicine for treating diabetes
CN102895537A (en) * 2011-07-27 2013-01-30 陈冠卿 Medicine treating diabetes

Also Published As

Publication number Publication date
CN1054524C (en) 2000-07-19

Similar Documents

Publication Publication Date Title
CN103083531B (en) Drug for treating diabetes
CN1475229A (en) Antifatigue compound Chinese medicine prescription and its preparation method
CN1103305A (en) Diabetes powder and its preparing method
CN1726953A (en) Combination for treating diabetes and complicating diseases, and preparation
CN1159050C (en) Compound traditional Chinese medicine preparation for treating type 2 diabetes
CN1137720C (en) Chinese medicine for treating diabetes and its complication
CN1054524C (en) Medicine composition for treating diabetes mellitus
CN1066332C (en) Hypoglycemic compound capsule
CN1054525C (en) Medicinal composition for treating diabetes involving lower jiao
CN1879783A (en) A medicine for treating diabetes
CN1058403C (en) A pharmaceutical composition for the treatment of diabetes
CN1062751C (en) Compound Chinese and western medicinal compsn. for treating 'down elimination' diabetes
CN1063644C (en) Compound Chinese and western medicinal compsn. for treating 'upper elimination' diabetes
CN113521134A (en) Traditional Chinese medicine composition for treating type II diabetes and application thereof
CN100339119C (en) Traditional Chinese medicine prepns. for treating diabete
CN1063645C (en) Compound Chinese and western medicinal compsn. for treating 'medium elimination' diabetes
CN1314160A (en) Oral pill for curing diabetes and its complication
CN1097333A (en) A kind of pure plant health preparation glycolipid disappears and method for making
CN1076622C (en) Chinese medicine for curing nephritis
CN1306830A (en) Medicine for treating type II diabetes
CN1238013C (en) Myocarditis treating Chinese medicine prepn
CN1183933C (en) Medicine for treating incomplete kidney function and its prepn
CN1363386A (en) Composition Chinese-medicinal herb pieces and preparing process thereof
CN1110176A (en) Oral drug for curing diabetes and complicated angiocardiopathy
CN1111426C (en) Diabetes treating medicine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Co-applicant after: Lin Yulin

Co-applicant before: Zong Yuhua

CB03 Change of inventor or designer information

Inventor after: Lin Yulin

Inventor after: Chen Jinyan

Inventor after: Lin Zuxian

Inventor after: Fu Chunfu

Inventor before: Chen Jinyan

Inventor before: Lin Zuxian

Inventor before: Fu Chunfu

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: CHEN JINYAN; LIN ZUXIAN; FU CHUNFU TO: LIN YULIN; CHEN JINYAN; LIN ZUXIAN;FU CHUNFU

C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee